Age, sex, and existing cardiovascular disease influence cholesterol response to semaglutide
As such, other mechanisms might exist
Nausea incidence with GLP-1 therapies varies by agent, dose, and population, but current research indicates that roughly one in five to one in two users experience some nausea, most often during the first weeks of therapy
The mean BMI was approximately 27.6 kg/m
This can range from a bit of itching and red bumps to more serious stuff like swelling and trouble breathing
Typical symptoms will include: Fatigue Breathlessness Loss of appetite Stomach problems Mouth ulcers Nerve damage Pins and needles Loss of sensation in fingers and toes Muscle weakness Sight and memory problems Mood changes and depression Palpitations Where does B12 come from